Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment
Cholesterol-conjugated 5-fluorouracil prodrugs were designed to be carried in vivo via low density lipoproteins (LDL) and subsequently undergo LDL-receptor-mediated internalisation into cancer cells. In vivo anti-cancer evaluation was performed using 5-fluorouracil-cholesterol conjugate in a mouse...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-08-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1420-3049/19/9/13177 |
| id |
doaj-52c1b38010c24b3cb3da1eec2654535f |
|---|---|
| record_format |
Article |
| spelling |
doaj-52c1b38010c24b3cb3da1eec2654535f2020-11-24T23:31:05ZengMDPI AGMolecules1420-30492014-08-01199131771318710.3390/molecules190913177molecules190913177Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer TreatmentAwwad A. Radwan0Fares K. Alanazi1Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi ArabiaKayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi ArabiaCholesterol-conjugated 5-fluorouracil prodrugs were designed to be carried in vivo via low density lipoproteins (LDL) and subsequently undergo LDL-receptor-mediated internalisation into cancer cells. In vivo anti-cancer evaluation was performed using 5-fluorouracil-cholesterol conjugate in a mouse model. The obtained prodrugs were more potent than 5-fluorouracil control drug at the same 5-fluorouracil content (3 mg·kg−1).http://www.mdpi.com/1420-3049/19/9/13177drug targetinganticancercholesteryl esters |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Awwad A. Radwan Fares K. Alanazi |
| spellingShingle |
Awwad A. Radwan Fares K. Alanazi Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment Molecules drug targeting anticancer cholesteryl esters |
| author_facet |
Awwad A. Radwan Fares K. Alanazi |
| author_sort |
Awwad A. Radwan |
| title |
Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment |
| title_short |
Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment |
| title_full |
Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment |
| title_fullStr |
Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment |
| title_full_unstemmed |
Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment |
| title_sort |
design and synthesis of new cholesterol-conjugated 5-fluorouracil: a novel potential delivery system for cancer treatment |
| publisher |
MDPI AG |
| series |
Molecules |
| issn |
1420-3049 |
| publishDate |
2014-08-01 |
| description |
Cholesterol-conjugated 5-fluorouracil prodrugs were designed to be carried in vivo via low density lipoproteins (LDL) and subsequently undergo LDL-receptor-mediated internalisation into cancer cells. In vivo anti-cancer evaluation was performed using 5-fluorouracil-cholesterol conjugate in a mouse model. The obtained prodrugs were more potent than 5-fluorouracil control drug at the same 5-fluorouracil content (3 mg·kg−1). |
| topic |
drug targeting anticancer cholesteryl esters |
| url |
http://www.mdpi.com/1420-3049/19/9/13177 |
| work_keys_str_mv |
AT awwadaradwan designandsynthesisofnewcholesterolconjugated5fluorouracilanovelpotentialdeliverysystemforcancertreatment AT fareskalanazi designandsynthesisofnewcholesterolconjugated5fluorouracilanovelpotentialdeliverysystemforcancertreatment |
| _version_ |
1725538855549927424 |